WARNING Metronidazole has been shown to be carcinogenic in mice and rats (see PRECAUTIONS). Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions described in the INDICATIONS AND USAGE section below.
Use: Labeled indications
- Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis , B. distasonis , B. ovatus , B. thetaiotaomicron…
- Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species and Fusobacterium species in adults.
- Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species…
- Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species in adults.
- Bone and Joint Infections , as adjunctive therapy, caused by Bacteroides species including the B. fragilis group in adults.
- Central Nervous System (CNS) Infections , including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group in adults.
- Lower Respiratory Tract Infections , including pneumonia, empyema and lung abscess, caused by Bacteroides species including the B. fragilis group in adults.
- Endocarditis caused by Bacteroides species including the B. fragilis group in adults.
Full indications and usage US FDA label
INDICATIONS AND USAGE Treatment of Anaerobic Bacterial Infections Metronidazole Injection is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection therapy. In a mixed aerobic and anaerobic infection, antibacterial drugs appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole Injection.
Metronidazole Injection is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol and penicillin.
- Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species and Peptostreptococcus species in adults and pediatric patients less than 4 months of age.
- Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species and Fusobacterium species in adults.
- Gynecologic Infections, including endometritis, endomyometritis, tubo-ovarian abscess and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species and Fusobacterium species in adults.
- Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species in adults.
- Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species including the B. fragilis group in adults.
- Central Nervous System (CNS) Infections, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group in adults.
- Lower Respiratory Tract Infections, including pneumonia, empyema and lung abscess, caused by Bacteroides species including the B. fragilis group in adults.
- Endocarditis caused by Bacteroides species including the B. fragilis group in adults. Prophylaxis Indication The prophylactic administration of Metronidazole Injection preoperatively, intraoperatively and postoperatively may reduce the incidence of postoperative infection in adult patients undergoing elective colorectal surgery which is classified as contaminated or potentially contaminated. Prophylactic use of Metronidazole Injection should be discontinued within 12 hours after surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism(s) so that appropriate therapy may be given (see DOSAGE AND ADMINISTRATION). Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole Injection and other antibacterial drugs, Metronidazole Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Contraindications
- Hypersensitivity to metronidazole or other nitroimidazoles
- Disulfiram within the past 2 weeks
- Alcohol or propylene glycol during and for 3 days after therapy
- Cockayne syndrome
Contraindications (US label) US FDA label
CONTRAINDICATIONS
- Hypersensitivity Metronidazole Injection is contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives.
- Psychotic Reaction with Disulfiram Use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. Do not administer metronidazole to patients who have taken disulfiram within the last two weeks (see PRECAUTIONS-Drug Interactions).
- Interaction with Alcohol Use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. Discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole (see PRECAUTIONS-Drug Interactions).
- Cockayne Syndrome Metronidazole Injection is contraindicated in patients with Cockayne syndrome. Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with Cockayne syndrome (see ADVERSE REACTIONS).
Dosing: Adult
- Anaerobic infections (IV, adults): Loading 15 mg/kg over 1 hour (about 1 g), then 7.5 mg/kg (about 500 mg) every 6 hours, starting 6 hours later
- Oral step-down (adults): 7.5 mg/kg (about 500 mg) every 6 hours
- Maximum: 4 g per 24 hours
- Severe hepatic impairment (Child-Pugh C): Reduce dose by 50%
- Hemodialysis: Give after the session or add a supplement
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Dosage, rate of administration, and duration of treatment are to be individualized and depend upon the indication for use, the patient’s age, weight, clinical condition and concomitant treatment, and on the patient’s clinical and laboratory response to the treatment. Recommended Dosage for the Treatment of Anaerobic Bacterial Infections The recommended dosage schedule for adults for the treatment of anaerobic infections is presented in the Table 1: Table 1.
Recommended Dosage Schedule for the Treatment of Anaerobic Bacterial Infections in Adults Loading Dose 15 mg/kg infused intravenously over one hour (approximately 1 gram for a 70-kg adult). Maintenance Dosage 7.5 mg/kg infused intravenously over one hour every six hours (approximately 500 mg for a 70-kg adult). The first maintenance dose should be instituted six hours following the initiation of the loading dose.
Parenteral therapy may be changed to oral metronidazole therapy when conditions warrant, based upon the severity of the disease and the response of the patient to treatment with Metronidazole Injection. The usual adult oral dosage is 7.5 mg/kg every six hours (approximately 500 mg for a 70-kg adult). A maximum of 4 grams should not be exceeded during a 24-hour period.
The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract and endocardium may require longer treatment. Recommended Dosage for the Treatment of Intra-Abdominal Infections in Pediatric Patients Less than 4 Months of Age: The recommended dosage schedule for pediatric patients less than 4 months of age for the treatment of intra-abdominal infections is described in Table 2 below.
These dosage schedules achieve drug exposures in pediatric patients similar to adults treated with Metronidazole Injection for this indication. Table 2. Recommended Dosage Schedule for the Treatment of Intra-Abdominal Infections in Pediatric Patients Less than 4 months of Age Post-menstrual age (Completed weeks) Loading Dose (mg/kg) Maintenance Dose The first maintenance dose is given 24 hours after the start of the loading dose.
(mg/kg) Dosing interval (hours) 23 to <34 15 7.5 12 34 to 40 15 7.5 8 >40 to 48 15 7.5 6 Recommended Dosage in Patients with Severe Hepatic Impairment For patients with severe hepatic impairment (Child-Pugh C), the metronidazole dose should be reduced by 50% (see CLINICAL PHARMACOLOGY and PRECAUTIONS). Recommended Dosage in Patients Undergoing Hemodialysis Hemodialysis removes significant amounts of metronidazole and its metabolites from systemic circulation.
The clearance of metronidazole will depend on the type of dialysis membrane used, the duration of the dialysis session, and other factors. If the administration of metronidazole cannot be separated from a hemodialysis session, supplementation of metronidazole dosage following a hemodialysis session should be considered, depending on the patient’s clinical situation (see CLINICAL PHARMACOLOGY).
Dosage Considerations in Geriatric Patients In elderly patients the pharmacokinetics of metronidazole may be altered and, therefore, monitoring of serum levels may be necessary to adjust the metronidazole dosage accordingly. Recommended Prophylaxis Dosage For surgical prophylactic use, to prevent postoperative infection in contaminated or potentially contaminated colorectal surgery, the recommended dosage schedule for adults is: a. 15 mg/kg infused over 30 to 60 minutes and completed approximately one hour before surgery; followed by b. 7.5 mg/kg infused over 30 to 60 minutes at 6 and 12 hours after the initial dose.
It is important that (1) administration of the initial preoperative dose be completed approximately one hour before surgery so that adequate drug levels are present in the serum and tissues at the time of initial incision, and (2) Metronidazole Injection be administered, if necessary, at 6-hour intervals to maintain effective drug levels. Prophylactic use of Metronidazole Injection should be limited to the day of surgery only, following the above guidelines.
Important Administration and Preparation Instructions Caution: Metronidazole Injection is to be administered by slow intravenous drip infusion only, either as a continuous or intermittent infusion. Additives should not be introduced into Metronidazole Injection, unless compatibility is known. If used with a primary intravenous fluid system, the primary solution should be discontinued during metronidazole infusion.
DO NOT USE EQUIPMENT CONTAINING ALUMINUM (e.g., NEEDLES, CANNULAE) THAT WOULD COME IN CONTACT WITH THE DRUG SOLUTION AS PRECIPITATES MAY FORM. Metronidazole Injection is incompatible with (includes but is not limited to): Aztreonam, Cefamandole nafate, Cefoxitin, Penicillin G. In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products (see DIRECTIONS FOR USE OF VIAFLEX PLUS PLASTIC CONTAINER).
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer unless the solution is clear and the seal is intact.
Dosing: Altered kidney function
Metronidazole is metabolized in the liver; kidney impairment does not change its own kinetics, but its hydroxy and acetate metabolites build up in kidney failure. The US label gives no kidney dose change. Hemodialysis removes 40% to 65% of a dose, so give it after the session or add a supplement; CAPD removes little and needs no change. Severe liver impairment (Child-Pugh C) needs a 50% dose cut.
Kidney function measure: Label PK uses CrCl (mL/min); no kidney bands.
Show full dosing details
- CrCl ≥60 mL/min
- No dose change: kidney impairment does not alter single-dose metronidazole kinetics (label).
- CrCl 30–59 mL/min
- No dose change: kidney impairment does not alter single-dose metronidazole kinetics (label).
- CrCl 15–29 mL/min
- No dose change: kidney impairment does not alter single-dose metronidazole kinetics (label).
- CrCl <15 mL/min (not on dialysis)
- No dose change: kidney impairment does not alter single-dose metronidazole kinetics (label). In end-stage kidney disease, peak levels of hydroxy-metronidazole were 2 times and of metronidazole acetate 5 times normal (label PK). Because metabolites accumulate in end-stage kidney disease, monitoring for metronidazole-associated adverse events is recommended (label).
- Hemodialysis (intermittent)
- Hemodialysis (4 to 8 hours) removes 40% to 65% of a dose. If dosing cannot be separated from the session, consider a supplemental dose after hemodialysis (label).
- Peritoneal dialysis
- No dose change on CAPD; a 7.5-hour peritoneal dialysis removed about 10% of a dose (label).
- CRRT
- Not in label; the cited CRRT review (Li 2020) gives no regimen for this drug. Specialist input.
- Dialyzable? Hemodialysis: yes (40% to 65% of a dose per 4- to 8-hour session, by membrane and duration). Peritoneal dialysis: little (about 10%) (label). Under 20% protein bound.
- Monitoring Neurologic symptoms (encephalopathy, cerebellar signs, seizures, peripheral or optic neuropathy, aseptic meningitis); liver function in hepatic impairment; INR with warfarin; lithium and creatinine with lithium (label).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual pediatric dose (label).
- eGFR 30–59
- No pediatric kidney dosing in label. Specialist input.
- eGFR 15–29
- No pediatric kidney dosing in label. Specialist input.
- eGFR <15 (not on dialysis)
- No pediatric kidney dosing in label. Specialist input.
- Hemodialysis (intermittent)
- No pediatric kidney dosing in label. Specialist input.
- Peritoneal dialysis
- No pediatric kidney dosing in label. Specialist input.
- CRRT
- No pediatric kidney dosing in label. Specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
Renal Impairment Decreased renal function does not alter the single-dose pharmacokinetics of metronidazole. Subjects with end-stage renal disease (ESRD; CL CR = 8.1±9.1 mL/min) and who received a single intravenous infusion of metronidazole 500 mg had no significant change in metronidazole pharmacokinetics but had 2-fold higher Cmax of hydroxy-metronidazole and 5-fold higher Cmax of metronidazole acetate, compared to healthy subjects with normal renal function (CL CR = 126 ± 16 mL/min).
Thus, on account of the potential accumulation of metronidazole metabolites in ESRD patients, monitoring for metronidazole associated adverse events is recommended (see PRECAUTIONS). Effect of Dialysis Following a single intravenous infusion or oral dose of metronidazole 500 mg, the clearance of metronidazole was investigated in ESRD subjects undergoing hemodialysis or continuous ambulatory peritoneal dialysis (CAPD).
A hemodialysis session lasting for 4 to 8 hours removed 40% to 65% of the administered metronidazole dose, depending on the type of the dialyzer membrane used and the duration of the dialysis session. If the administration of metronidazole cannot be separated from the dialysis session, supplementation of metronidazole dose following hemodialysis should be considered (see DOSAGE AND ADMINISTRATION).
A peritoneal dialysis session lasting for 7.5 hours removed approximately 10% of the administered metronidazole dose. No adjustment in metronidazole dose is needed in ESRD patients undergoing CAPD.
Dosing: Pediatric
- Approved ages
- Intra-abdominal infections in infants under 4 months; other indications in adults (IV label).
- Usual dose
- Under 4 months, intra-abdominal infection: loading dose 15 mg/kg, then 7.5 mg/kg starting 24 hours later, every 12 hours (postmenstrual age 23 to under 34 weeks), every 8 hours (34 to 40 weeks) or every 6 hours (over 40 to 48 weeks) (label Table 2).
- Maximum dose
- As above (label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
Pediatric Use Pediatric Patients Less than 4 Months of Age The safety and effectiveness of Metronidazole Injection have been established for the treatment of intraabdominal infections in pediatric patients from birth to less than 4 months. Use of Metronidazole Injection in this age group is supported by evidence from data in adults with additional pharmacokinetic and safety data in pediatric patients from birth to less than 4 months of age.
A partially randomized, open-label, phase 2/3 study of intravenous Metronidazole Injection in combination with other intravenous antibacterial drugs was conducted in 62 preterm infants (≤ 33 weeks gestational age at birth, and postnatal age <121 days) and 55 late pre-term and term infants (≥ 34 weeks gestational age at birth, and postnatal age <121 days), with complicated intra-abdominal infections. The primary objective of this study was to evaluate the safety of metronidazole-containing regimens, which were administered for up to 10 days.
The adverse reactions reported in patients receiving metronidazole-containing regimens were comparable to patients receiving other antibacterial regimens in the study and generally similar to adverse reactions described in adults. The safety and effectiveness of Metronidazole Injection in pediatric patients less than 4 months of age have not been established for (1) the treatment of anaerobic infections other than intra-abdominal infections or for (2) prophylaxis for postoperative infections (see INDICATIONS AND USAGE, CLINICAL PHARMACOLOGY, Pediatric Patients and DOSAGE AND ADMINISTRATION).
Pediatric Patients 4 Months of Age and Older The safety and effectiveness of Metronidazole Injection in pediatric patients 4 months of age and older have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. In geriatric patients, monitoring for metronidazole associated adverse events is recommended (see CLINICAL PHARMACOLOGY, PRECAUTIONS). Decreased liver function in geriatric patients can result in increased concentrations of metronidazole that may necessitate adjustment of metronidazole dosage (see DOSAGE AND ADMINISTRATION).
Dosage forms
Philippines
- Tablet: 250 mg, 500 mg
- ) solution for i.v. infusion: 1 mg/mL (500 mg/100 mL, 5 mg/mL (500 mg/100 mL
- Solution for iv infusion: 5 mg/mL, 500 mg per 100 mL, 500 mg/100 mL
- Film-coated tablet: 500 mg
- ) solution for intravenous infusion: 5 mg/mL (500 mg/100 mL
- Oral suspension: 25 mg/mL, 125 mg/5 mL, 250 mg/5 mL
- Suspension: 125 mg/5 mL
- ) solution for injection: 5 mg/mL (500 mg/100 mL
- ) solution for iv infusion: 5 mg/mL (500 mg/100 mL, 500 mg/100 mL (5 mg/mL
- Solution for i.v. infusion: 5 mg/mL, 500 mg, 500 mg/100 mL
and 7 more forms; see the products table.
Registered products in the Philippines
173 products registered with the Food and Drug Administration (FDA) Philippines list Metronidazole as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products173
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AcumetMetronidazole | 5 mg/mL [500 mg/100 mL (0.5% w/v)] Solution for Intravenous Infusion.100 mL-net content Polyethylene Bottle with Euro Head Cap (Box of 1's) | Rx | Aculife Healthcare Private LimitedIndia | Blue Global (FZE) | DRP-14852 | Jan 24, 2029 | |
AffozoleMetronidazole | 500 mg/100 mL Solution for Intravenous InfusionFFS LDPE Bottle x 100 mL | Rx | Ahlcon Parenterals (India) Ltd.India | Affomedz, Inc.Importer: I.E. Medica, Inc. | DRP-5630-01 | Oct 17, 2029 | |
AldazoleMetronidazole (as Benzoate) | 125 mg/5 mL Suspension (Strawberry Flavor)Amber Bottle x 15 mL and 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-2440-01 | May 19, 2031 | |
AldazoleMetronidazole | 500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-3377-01 | Mar 9, 2030 | |
AldezolMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for IV InfusionFFS LDPE Bottle x 100 mL (Box of 1's) | Rx | Ahlcon Parenterals (India) Ltd.India | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-5629-03 | Oct 17, 2029 | |
AldezolMetronidazole | 5mg/mL (500mg/100mL) Solution for IV InfusionWhite transparent LDPE bottle x 100 mL (Box of 1's) | Rx | Albert David LimitedIndia | Medethix, Inc. | DRP-7822 | Apr 10, 2031 | |
Altozol IVMetronidazole | 500 mg/100 mL Solution for Intravenous InfusionFFS LDPE Bottle x 100 mL (Box of 1's) | Rx | Ahlcon Parenterals (India) Ltd.India | Altomed Pharmaceuticals, Inc.Importer: I.E. Medica, Inc. | DRP-5630-03 | Oct 17, 2029 | |
AmbidazolMetronidazole (as Benzoate) | 125 mg/5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5469 | Mar 12, 2027 | |
AmbidazolMetronidazole | 250 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Drugmaker’s Laboratories Inc.Philippines | — | DR-XY24776 | Feb 8, 2029 | |
AmibazoleMetronidazole | 500 mg TabletBlister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-1001-01 | Jan 30, 2028 | |
AmizolMetronidazole (as Benzoate) | 125 mg/5 mL Suspension (Strawberry Flavor)Amber Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Euro-Health Care Exponents, Inc. | DRP-2440-02 | May 8, 2031 | |
AmizolMetronidazole | 5 mg/ mL (500 mg/ 100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's) | Rx | Eurolife Healthcare Pvt. LtdIndia | Medirich Pharma Distribution Corp.Importer: Aglobal Care, Inc. | DRP-13577-01 | Mar 13, 2028 | |
AmizolMetronidazole | 500 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Foramen Products Corporation | DR-XY22624 | Mar 5, 2027 | |
AmridMetronidazole | 500 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Trumed PharmaceuticalsImporter: Hexagon Pharmaceuticals | DRP-986-02 | Jun 13, 2027 | |
AnerobizolMetronidazole | 5 mg/mL Solution for Intravenous InfusionPolypropylene Plastic Container x 100mL Box of 1's | Rx | Amanta Healthcare Ltd.India | Endure Medical, Inc. | DR-XY32881 | Feb 21, 2031 | |
AntizoalMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1’s) | Rx | Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China | Aglobal Care, Inc. | DRP-5460 | Jul 31, 2028 | |
ApzoleMetronidazole | 500 mg/100 mL Solution for I.V. InfusionPolypropylene Plastic Bottle x 100 mL (Box of 1’s) | Rx | Shijiazhuang No. 4 Pharmaceutical Co. LtdChina | Pharmazel Inc.Importer: Apothecon Drug Int’l Corp.Trader: Shanghai Pharmaceutical Co., Ltd. | DRP-6583 | Aug 14, 2028 | |
AxagylMetronidazole | 500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL (Box of 1’s) | Rx | AXA Parenterals LimitedIndia | Sonchel Pharma DistributorsImporter: Ambica International Corporation | DRP-6449 | Mar 5, 2030 | |
Axamet-IVMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionLow Density Polyethylene (LDPE) Plastic Bottle x 100 mL (net content) (Box of 1's) | Rx | Axa Parenterals LimitedIndia | Brady Pharma Inc. | DRP-8507 | Oct 22, 2029 | |
BacdazoleMetronidazole | 500 mg TabletAlu-PVC Blister Pack x 10's (Box of 100's) | Rx | Scheele Laboratories Phils., Inc.Philippines | — | DRP-3941 | Jan 24, 2032 | |
BacimexMetronidazole | 500 mg/100 mL (0.5% w/v) Solution for InjectionPlastic Bottle x 100 mL (Box of 1's) | Rx | Otsuka Pharmaceutical India Private LimitedIndia | Zuellig Pharma CorporationImporter: Otsuka (Philippines) Pharmaceutical, Inc. | DRP-1541 | Apr 25, 2028 | |
BerrydazoleMetronidazole (As Benzoate) | 250 mg/5mL Oral SuspensionAmber boston round glass bottle with white aluminum screw cap x 30 mL (net content) & 60 mL (net content) [Box of 1's] | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Folares Pharmaceuticals, Inc. | DR-XY47509 | Nov 29, 2026 | |
BestdazoleMetronidazole | 5 mg /mL (500 mg/100 mL) Solution for I.V. InfusionClear glass bottle x 100 mL (net content) (Box of 1's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Best ClearImporter: Euro-Care Products Philippines | DRP-8546-02 | Nov 6, 2029 | |
BluemedzoleMetronidazole | 5 mg / mL (500 mg/100 mL) Solution for I.V. InfusionClear glass bottle x 100 mL (net content) (Box of 1's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Blue Medceuticals Marketing Corp.Importer: Euro-Care Products Philippines | DRP-8546-03 | Nov 6, 2029 | |
CetazMetronidazole | 5 mg/mL (500mg/100mL) Solution for Injection (IV Infusion)LDPE vial X 100 mL Box of 1's | Rx | AISHWARYA HEALTHCAREIndia | QUALIFIRST HEALTH INC.Trader: ALKEM LABORATORIES LTD. | DRP-541 | May 19, 2027 | |
CoremedazoleMetronidazole | 5 mg/ mL (500 mg/ 100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Core Fidelis Pharmaceutical, Inc.Importer: AGlobal Care, Inc. | DRP-13577-05 | Mar 13, 2028 | |
DarylMetronidazole (as benzoate) | 125 mg/5 mL Oral Suspension60 mL Amber Glass Bottle (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories, Inc.Philippines | — | DRP-5275 | Aug 15, 2030 | |
DazoledMetronidazole | 500 mg Film-Coated TabletAlu/Green PVC Blister Pack x 10’s (Box of 100’s) | Rx | Genom Biotech Pvt. Ltd.India | Eliset Pharmaceutical, Inc.Importer: Nelpa Lifesciences, Inc. | DRP-17141-01 | Oct 7, 2030 | |
DazometMetronidazole | 500 mg Film-Coated TabletAluminum Foil Strip x 4's Box of 100's | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY33848 | Dec 2, 2028 | |
DazometMetronidazole | 500 mg/100 mL Solution For Iv InfusionUSP Type I clear glass vial with gray rubber closure and aluminum overseal cap with blue flip-off cap x 100 mL (Box of l’s) | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY33847 | Aug 5, 2027 | |
DelexigylMetronidazole | 500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL LDPE plastic container x 100 mL (Box of 1’s) | Rx | AXA Parenterals LimitedIndia | Delex Pharma International, Inc.Importer: Ambica International Corporation | DRP-6449-02 | Mar 5, 2030 | |
DymetrazoleMetronidazole | 500 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Nurturemed Pharma Inc.Trader: Eadriex Pharmaceuticals Phils., Inc. | DRP-2420-02 | Feb 17, 2027 | |
DynazoleMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1’s) | Rx | Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China | DYNASTY PHARMACEUTICALSImporter: Aglobal Care, Inc. | DRP-5460-02 | Jul 31, 2028 | |
EastmezolMetronidazole | 5 mg/mL (0.5% w/v) Solution for IV InfusionLDPE Plastic Bottle x 100 mL (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India | Core Fidelis Pharmaceutical, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4259-03 | May 19, 2037 | |
EndiglyMetronidazole | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-6166 | Jun 15, 2030 | |
ErzolMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene (PP) plastic bottle x 100 mL (net content). (Box of 1's.) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-8458 | Oct 10, 2029 | |
EurogylMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. Infusion100 mL USP Type III clear and colorless glass infusion bottle (Box of 1's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Euro-Care Products Philippines | DR-XY45126 | Feb 23, 2031 | |
EurometMetronidazole | 500 mg/100 mL (5 mg/mL) Solution for IV InfusionLDPE Plastic Bottle x 100 mL (Box of 1's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-4800 | Mar 18, 2031 | |
FlagexMetronidazole | 500mg TabletBlister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DRP-1001 | Jan 30, 2028 | |
FlagidinMetronidazole | 500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-4034-07 | Sep 24, 2028 | |
FlagimaxMetronidazole | 500 mg TabletPaper Foil Strip x 10's (Box of 100's) | Rx | Sydenham Laboratories, Inc.Philippines | Alberta's Pride International Indigo, Inc. | DR-XY47671 | Jan 19, 2027 | |
FlagylMetronidazole | 1 mg/mL (500 mg/100 mL) Solution for I.V. infusionPoly (vinylchloride) flexible plastic bag (Viaflex) in 100 mL (net content) with transparent polypropylene overpouch | Rx | Baxter Healthcare S. A.Ireland | Importer: SANOFI-AVENTIS PHILIPPINES, INC | DRP-182 | Nov 21, 2027 | |
FlagylMetronidazole (as Benzoate) | 125 mg/5 mL Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | SANOFI-AVENTIS PHILIPPINES, INCTrader: Eadriex Pharmaceuticals Phils., Inc. | DRP-5591-05 | Feb 7, 2028 | |
FlagylMetronidazole (as benzoate) | 25 mg/mL Oral Suspension60 mL Amber Glass Bottle with Gold Pilfer-proof Metal Cap (Box of 1's) | Rx | PT. Guardian PharmatamaIndonesia | Importer: Sanofi-Aventis Philippines, Inc.Trader: PT. Aventis Pharma | DR-9040 | Mar 23, 2027 | |
Flagyl ForteMetronidazole | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | PT Kalventis Sinergi FarmaIndonesia | Importer: sanofi-aventis Philippines, Inc. | DRP-009 | Mar 12, 2031 | |
FlagyzoleMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for Intravenous InfusionUSP Type II Glass Vial x 100 mL (Box of 1's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DR-XY45437 | Jun 10, 2031 | |
Flamibazid 500Metronidazole | 500 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-986 | Jun 13, 2027 | |
FlatroMetronidazole | 500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE Plastic Container x 100 mL (Box of 1’s) | Rx | AXA Parenterals LimitedIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-6449-10 | Mar 5, 2030 | |
FlazoleMetronidazole (as Benzoate) | 125 mg/5 mL Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | 8th Green Care Pharma Inc.Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-5591-02 | Feb 7, 2028 | |
ForamebexMetronidazole | 125 mg/5mL SuspensionAmber Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Solvang Pharmaceuticals, Inc.Trader: Foramen Products Corporation | DR-XY21875 | Oct 22, 2030 | |
FrotinMetronidazole | 250 mg Vaginal SuppositoryPVC Peel-off Container x 10's (Box of 100's) | Rx | Y.S.P. Industries (M) SDN. BHD.Malaysia | Importer: Yung Shin (Philippines), Inc. | DR-XY47819 | Mar 15, 2027 | |
G-TrozoleMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for IV InfusionFFS LDPE Bottle x 100 mL (Box of 1's) | Rx | Ahlcon Parenterals (India) Ltd.India | GPC Geo Pharma CorporationImporter: I.E. Medica, Inc. | DRP-5629-01 | Oct 17, 2029 | |
GodazoleMetronidazole | 500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE Plastic Container x 100 mL (Box of 1’s) | Rx | AXA Parenterals LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation | DRP-6449-09 | Mar 5, 2030 | |
GonidazoleMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for IV InfusionPlastic Container x 100 mL (Box of 1's) | Rx | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals & Pharmaceuticals Ltd.)India | Applied Pharmaceutical DistributionImporter: Medinova Pharmaceutical Inc. | DRP-8098-01 | Sep 27, 2028 | |
GorondazMetronidazole | 5 mg / mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene (PP) plastic bottle x 100 mL (net content) (Box of 1's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Applied Pharmaceutical Distribution IncImporter: AMB HK Enterprises Inc. | DRP-8458-04 | Oct 10, 2029 | |
JinzoleMetronidazole (as Benzoate) | 125 mg/5 mL Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-5591 | Feb 7, 2028 | |
JinzoleMetronidazole | 500 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Eadriex Pharmaceuticals Phils., Inc. | DRP-2420 | Feb 17, 2027 | |
MedgylMetronidazole | 125 mg/5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DR-XY18460 | Apr 30, 2030 | |
MedgylMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for Injection (I.V. Infusion)Type II Clear and Colorless Glass Vial x 100 mL (Box of 1's) | Rx | Taiwan Biotech Co., Ltd.China | Medhaus Pharma, IncorporatedImporter: Interhealthcare Pharmaceuticals, Inc. | DR-XY33042 | Feb 26, 2027 | |
MedgylMetronidazole | 500 mg TabletAlu/PVC Clear Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma Inc. | DR-XY24567 | Oct 27, 2028 | |
Medgyl IVMetronidazole | 500 mg /100 mL Solution for Intravenous InfusionFFS LDPE Bottle x 100 mL Box of 1's | Rx | Ahlcon Parenterals (India) Ltd.India | Medhaus Pharma, IncorporatedImporter: I.E. Medica Inc. | DRP-5630-02 | Oct 17, 2029 | |
MedicazolMetronidazole | 5 mg/mL (500 mg/100 mL) Solution For I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1's) | Rx | Shijiazhuang No.4 Pharmaceutical Co., Ltd.China | Medicamenta Inc.Importer: Aglobal Care, Inc. | DRP-5460-03 | Jul 31, 2028 | |
MedizoleMetronidazole | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Medico Remedies LimitedIndia | Medethix, Inc. | DRP-6688 | May 20, 2029 | |
MedzolMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for Intravenous Infusion (I.V.)Polypropylene Infusion bottle with pull open cover x 100 mL (Box of 1’s) | Rx | SHIJIAZHUANG NO.4 PHARMACEUTICAL CO., LTD.China | APOTHECON DRUG INT’L CORP.Trader: SHANGHAI PHARMACEUTICAL CO., LTD. | DR-XY43080 | Mar 17, 2027 | |
MenizoleMetronidazole (as Benzoate) | 125 mg/5 mL Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-5591-01 | Feb 7, 2028 | |
MenizoleMetronidazole | 500 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-2420-01 | Feb 17, 2027 | |
MetametMetronidazole | 500 mg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's); Alu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Drugmaker’s Laboratories Inc.Philippines | — | DRP-5468 | Feb 15, 2030 | |
MetdazidMetronidazole | 5 mg/mL (0.5% w/v) Solution for IV InfusionLDPE Plastic Bottle x 100 mL (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India | Euparex Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4259-02 | Apr 16, 2037 | |
METRAZOLMetronidazole | 500 mg/100 mL Solution for I.V. InfusionPolypropylene infusion bottle (w/ pull open cover) x 100 mL (Box of 1’s) | Rx | Shijiazhuang No. 4 Pharmaceutical Co. LtdChina | D & G PharmaImporter: Apothecon Drug Int’l Corp.Trader: Shanghai Pharmaceutical Co., Ltd | DRP-4192 | Aug 14, 2028 | |
Metrinox IVMetronidazole | 500 mg per 100 mL Solution for Infusion (IV)Type II Glass Bottle with rubber stopper and blue flip-off seal x 100 mL (Box of 1's) | Rx | Euro-Med Laboratories Phil., Inc.Philippines | — | DR-XY29518 | Nov 14, 2036 | |
MetrisMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionNon PVC (Polypropylene) Bag x 100 mL | Rx | OTSUKA PHARMACEUTICAL INDIA PRIVATE LIMITEDIndia | OTSUKA (PHILIPPINES) PHARMACEUTICAL, INC. | DR-XY42249 | Jul 23, 2028 | |
Metro-BrillMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene (PP) plastic bottle x 100 mL (net content). (Box of 1’s) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Rcbrilliant Pharma CorpImporter: AMB HK Enterprises Inc. | DRP-8458-06 | Oct 10, 2029 | |
MetrocareMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100mL (Box of 1's) | Rx | Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China | Euro-Care Products PhilippinesImporter: Aglobal Care, Inc. | DRP-5460-04 | Jul 31, 2028 | |
MetroclearMetronidazole | 500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE Plastic Container x 100 mL (Box of 1’s) | Rx | AXA Parenterals LimitedIndia | CV Clearvue Pharma, Inc.Importer: Ambica International Corporation | DRP-6449-05 | Mar 5, 2030 | |
MetrocorMetronidazole | 5 mg/mL (0.5% w/v) Solution for IV InfusionLDPE Plastic Bottle x 100 mL (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India | Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4259 | Mar 8, 2038 | |
MetrodenMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene (PP) plastic bottle x 100 mL (net content) (Box of 1's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Cyden Medicale Trading Inc.Importer: AMB HK Enterprises Inc. | DRP-8458-02 | Oct 10, 2029 | |
MetrogemMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionClear glass bottle x 100 mL (net content) Box of 1's | Rx | Furen Pharmaceutical Group Co., Ltd.China | West Wing Pharma Sales Inc.Importer: Euro-Care Products Philippines | DRP-8546 | Nov 6, 2029 | |
MetrogilMetronidazole | 5 mg/mL Solution for Injection (I.V.)LDPE bottle x 100 mL (Box of 1's) | Rx | Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-7883 | Oct 11, 2028 | |
MetrogylMetronidazole | 10 mg/g (1% w/w) Topical GelAluminum Tube x 10 g and 30 g (Box of 1's) | Rx | Unique Pharmaceutical Laboratories (A Div. of J.B. Chemicals & Pharmaceuticals Limited)India | JBCPL Philippines Inc. | DRP-8314 | Feb 24, 2028 | |
MetrolevMetronidazole | 500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL (Box of 1’s) | Rx | AXA Parenterals LimitedIndia | HLM Pharmaceutical Inc.Importer: Ambica International Corporation | DRP-6449-08 | Mar 5, 2030 | |
MetroneedMetronidazole | 500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Checktrade Pharma, Inc.Importer: Ambica International Corporation | DRP-4034-02 | Sep 24, 2028 | |
Metronex SMetronidazole | 5 mg/mL (500 mg/100 mL) Solution For Injection (IV Infusion)Type-II Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with Flip-off Cap x 100 mL (Box of 1's) | Rx | Cotec Healthcare Pvt. Ltd.India | Despina Pharma Inc. | DRP-18429 | Jul 8, 2031 | |
MetronizolMetronidazole | 5 mg/ mL (500 mg/ 100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Onicare Pharma Trading & General MerchandiseImporter: AGlobal Care, Inc. | DRP-13577-03 | Mar 13, 2028 | |
MetronovaMetronidazole | 500 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Celogen Generics Private Ltd. (Unit II)India | Medinova Pharmaceutical Inc. | DRP-11953 | May 24, 2027 | |
Metronova IVMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for IV InfusionPlastic Container x 100 mL (Box of 1's) | Rx | Unique Pharmaceutical Labs. (A Division of J.B. Chemicals & Pharmaceutical Ltd.)India | Medinova Pharmaceutical Inc. | DRP-8098 | Sep 27, 2028 | |
Metronova IVMetronidazole | 5mg/mL (500mg/100mL) Solution for Injection (IV Infusion)White LDPE Bottle Sealed with Cap x 100mL in LDPE Plastic Film Pouche (Box of 1's) . | Rx | Eurolife Healthcare Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-17295 | Nov 11, 2030 | |
MetronyMetronidazole | 5 mg / mL (500 mg / 100 mL) Solution for I.V. InfusionClear glass bottle x 100 mL (net content) (Box of 1's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-8546-01 | Nov 6, 2029 | |
MetrosaphMetronidazole | 5 mg/mL (500 mg/100 mL) Solution For Injection (IV Infusion)White LDPE Container Sealed with Cap x 100 mL (Box of 1's) | Rx | Althea Phama Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-12535 | May 18, 2032 | |
Metrosaph-500Metronidazole | 500 mg Film-Coated TabletAlu/Green PVC Blister Pack x 10's (Box of 100's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-17141 | Oct 7, 2030 | |
MetrosaveMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1’s) | Rx | Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China | Savelink Pharma And Trading Co.Importer: Aglobal Care, Inc. | DRP-5460-06 | Jul 31, 2028 | |
MetrosolMetronidazole | 500 mg/100 mL Solution for I.V. Infusion100 mL LDPE Bottle (Box of 1's) | Rx | Marion Laboratories (Pvt) Ltd.Pakistan | Sahar International Trading, Inc. | DR-XY39985 | Mar 8, 2028 | |
MetrotonMetronidazole | 5 mg/ mL (500 mg/ 100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's) | Rx | Eurolife Healthcare Pvt. Ltd.India | McTon Pharma Inc.Importer: AGlobal Care, Inc | DRP-13577-06 | Mar 13, 2028 | |
MetroveeMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for Injection (IV Infusion)Transparent PP Infusion Bottle Sealed with Cap x 100 mL (Box of l's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Euro-Care Products Philippines | DRP-12534 | Aug 30, 2027 | |
MetroviaMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1’s) | Rx | Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China | Basic Pharmaceutical CorporationImporter: Aglobal Care, Inc. | DRP-5460-07 | Jul 31, 2028 | |
MetrovinMetronidazole | 5 mg/mL Solution for I.V. InfusionLDPE Plastic Bottle x 100 mL (net content) (Box of 1's) | Rx | Aishwarya HealthcareIndia | Arvincare Pharma Inc | DRP-5560 | Feb 3, 2027 | |
MetroxcelMetronidazole | 5 mg/mL (500 mg/ 100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Excelpharm CorporationImporter: Aglobal Care, Inc. | DRP-13577-04 | Mar 13, 2028 | |
MetroxidMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for IV Infusion100 mL USP Type II Clear and Colorless Glass Vial (Box of 1's) | Rx | Utopian Co., Ltd.Thailand | Lakeside Pharmaceuticals Phil., Inc. | DR-XY32450 | Jul 3, 2030 | |
MetrozedMetronidazole (as benzoate) | 125mg/5mL Oral SuspensionDark Amber Color PET Bottle Sealed with ROPP Cap x 60mL, 100mL and 120mL (Box of 1's) | Rx | S Kant Healthcare Ltd.India | Medinova Pharmaceutical Inc. | DRP-17084 | Sep 23, 2030 | |
MetrozenMetronidazole | 5 mg / mL (500 mg / 100 mL) Solution for I.V. InfusionPolypropylene (PP) plastic bottle x 100 mL (net content). (Box of 1's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Genzen Pharmaceutical TradingImporter: AMB HK Enterprises Inc. | DRP-8458-05 | Oct 10, 2029 | |
MetrozoleMetronidazole (as benzoate) | 125 mg/5 mL SuspensionAmber Boston Round Bottle x 60 mL Box of 1's | Rx | Diamond Laboratories Inc.Philippines | Rilem Pharma Corp. | DRP-7068 | Oct 5, 2027 | |
MetrozoleMetronidazole | 500 mg TabletAlu/PVC Blister pack x 20's (Box of 100’s) | Rx | Diamond Laboratories Inc.Philippines | Rilem Pharma Corp. | DRP-7107 | Jul 16, 2027 | |
MetrynalMetronidazole | 5 mg/mL (500 mg/ 100 mL) Solution for Injection (IV Infusion)USP Type II colorless and transparent glass bottle with bromobutyl rubber closure and aluminum cap x 100 mL (net content) Box of 10's | Rx | Dai Han Pharm. Co., Ltd.Republic of Korea | JLT PHARMA INC. | DRP-8759 | Mar 11, 2031 | |
MetzoleMetronidazole | 500 mg TabletClear PVC Blister Pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories Inc.Philippines | — | DRP-8249 | Jul 15, 2031 | |
MistolMetronidazole | 500 mg Vaginal SuppositoryWhite PVC/ PE Strip of 5's (Box of 10's) | Rx | Kusum Healthcare Pvt. Ltd (Block II)India | Kusum Healthcare Private Limited Branch Office | DR-XY46738 | Mar 13, 2030 | |
MoniliasolMetronidazole (as Benzoate) | 125 mg/ 5 mL SuspensionAmber Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DR-XY24088 | Apr 26, 2030 | |
MoniliasolMetronidazole (as Benzoate) | 500 mg TabletBlister Pack x 10's (Box of 100's) | Rx | LLOYD LABORATORIES, INC.Philippines | Trader: VITALINK HEALTH PRODUCTS, INC. | DR-XY19237-B | Oct 27, 2030 | |
MordoleMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1's) | Rx | SHIJIAZHUANG NO. 4 PHARMACEUTICAL CO., LTD.China | ELLEBASY MEDICALE TRADINGImporter: AGLOBAL CARE, INC | DRP-5460-01 | Jul 31, 2028 | |
Navgyl ForteMetronidazole | 500 mg tabletAlu-PVC blister Pack x 10's (Box of 100's) | Rx | Scheele Laboratories Phils., Inc.Philippines | JN Carlo Pharmaceuticals Distributor | DRP-3941-01 | Jan 24, 2027 | |
Navgyl-500Metronidazole | 5 mg/ mL (500 mg/ 100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's) | Rx | Eurolife Healthcare Pvt. Ltd.India | JN Carlo Pharmaceuticals DistributorImporter: Aglobal Care, Inc. | DRP-13577-02 | Mar 13, 2028 | |
NeorobiaMetronidazole | 5 mg/mL (500mg/100mL) Solution for I.V. InfusionClear glass bottle x 100 mL (net content) (Box of 1's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Neo Care Philippines, Inc.Importer: Euro-Care Products Philippines | DRP-8546-04 | Nov 6, 2029 | |
NeorobicMetronidazole | 500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL Box of 1’s | Rx | AXA Parenterals LimitedIndia | Neo-Care PhilippinesImporter: Ambica International Corporation | DRP-6449-07 | Mar 5, 2030 | |
NEOROBICMetronidazole | 5mg/mL (500mg/100mL) Solution for Injection (IV Infusion)White LDPE Bottle Sealed with Cap x 100mL in LDPE Plastic Film Pouch Box of 1's | Rx | Eurolife Healthcare Pvt. Ltd.India | Neo Care Philippines, Inc.Importer: Medinova Pharmaceutical Inc. | DRP-17295-01 | Nov 11, 2030 | |
NewmetMetronidazole | 500 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | United Pharma Plus (Unipharma) Inc.Importer: Ambica International Corporation | DRP-4034-06 | Sep 24, 2028 | |
NewmetMetronidazole | 500 mg/100 mL Solution for Intravenous InfusionFFS LDPE Bottle x 100 mL | Rx | Ahlcon Parenterals (India) Ltd.India | United Pharma Plus Inc.Importer: I.E. Medica, Inc. | DRP-5630 | Oct 17, 2029 | |
NicozoleMetronidazole | 5 mg/mL Solution for I.V. InfusionLDPE Plastic Bottle x 100 mL (net content) (Box of 1's) | Rx | Aishwarya HealthcareIndia | Thymed EnterprisesImporter: Arvincare Pharma Inc | DRP-5560-01 | Feb 3, 2027 | |
NicozoleMetronidazole | 500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL Box of 1’s | Rx | AXA Parenterals LimitedIndia | Thymed EnterprisesImporter: Ambica International Corporation | DRP-6449-11 | Mar 5, 2030 | |
NidazMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Aglobal Care, Inc. | DRP-13577 | Mar 13, 2028 | |
NidazoprimeMetronidazole | 500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL (Box of 1’s) | Rx | AXA Parenterals LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-6449-01 | Mar 5, 2030 | |
NirmetMetronidazole | Solution for Intravenous Infusion 5 mg/mL (500 mg/100 mL)LDPE bottle x 100 mL Box of 1's | Rx | Aculife Healthcare Private LimitedIndia | Brady Pharma Inc. | DR-XY38936 | Jan 7, 2031 | |
NoneMetronidazole (as Benzoate) | 125 mg/5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Scheele Laboratories Phils. Inc.Philippines | — | DRP-2059 | Mar 12, 2031 | |
NoneMetronidazole (as Benzoate) | 125 mg/5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Drugmaker's Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-5469-01 | Mar 12, 2027 | |
NoneMetronidazole | 5 mg/ mL (500 mg/ 100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Connectwell Pharma Inc.Importer: Aglobal Care, Inc. | DRP-13577-07 | Mar 13, 2028 | |
NoneMetronidazole | 5 mg/mL (0.5% w/v) Solution for IV InfusionLDPE Plastic Bottle x 100 mL (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India | RiteMED Phils., Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4259-04 | Apr 16, 2037 | |
NoneMetronidazole | 500 mg Solution for I.V. InfusionPlastic Container x 100 mL (Twin Port - Ecoflac Plus) | Rx | B. Braun Medical Industries Sdn. Bhd.Malaysia | B. Braun Medical Supplies, Incorporated | DR-XY14162 | Feb 9, 2031 | |
NoneMetronidazole | 500 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | Stallion Laboratories Pvt. Ltd.India | PharmaVital Corp.Importer: Ambica International Corporation | DRP-12008-01 | May 30, 2027 | |
NoneMetronidazole | 500 mg TabletAlu / PVC Blister Pack x 10's (Box of 100’s) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-12008-02 | May 30, 2027 | |
NoneMetronidazole | 500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | AM-Europharma CorporationPhilippines | — | DRP-2377 | Apr 28, 2029 | |
NoneMetronidazole | 500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-4034-05 | Sep 24, 2028 | |
NoneMetronidazole | 500 mg TabletAlu/Clear PVC Blister pack x 10's and 20's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Drugmaker's Laboratories, Inc. | DRP-5468-02 | Feb 15, 2030 | |
NoneMetronidazole | 500 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Qualifirst Health Inc.Importer: Hexagon Pharmaceuticals | DRP-986-03 | Jun 13, 2027 | |
NoneMetronidazole | 500 mg/100 mL Solution for I.V. Infusion100 mL Type II Glass Vial with Blue Flip-off Cap | Rx | Grand Pharmaceutical (China) Co., Ltd.China | First Global Trading Corporation | DR-XY42300 | Aug 1, 2028 | |
NoneMetronidazole | 500 mg/100 mL Solution for IV InfusionPolypropylene Bottle x 100 mL | Rx | Sichuan Kelun Pharmaceutical Co., Ltd.China | Sahar International Trading, Inc,Importer: Nueva Sunshine Phils., Inc. | DRP-7705 | Sep 1, 2030 | |
OnizoleMetronidazole | 500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Starpharm, Inc.Importer: Ambica International Corporation | DRP-4034-03 | Sep 24, 2028 | |
Onizole VialMetronidazole | 500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL (Box of 1’s) | Rx | AXA Parenterals LimitedIndia | Starpharm, Inc.Importer: Ambica International Corporation | DRP-6449-04 | Mar 5, 2030 | |
PatrizoleMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for Intravenous InfusionUSP Type II Glass Vial x 100 mL (Box of 1's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Nutramedica Inc.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-16242-02 | Jun 10, 2031 | |
PatrylMetronidazole (as Benzoate) | 125 mg/5 mL Suspension (Strawberry Flavor)Amber Bottle x 15 mL and 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Nutramedica, Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-2440 | Apr 30, 2030 | |
PatrylMetronidazole | 500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Nutramedica Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-3377 | Mar 9, 2030 | |
PolgylMetronidazole | 5 mg/ mL (500 mg/ 100 mL) Solution for I.V. InfusionPolypropylene (PP) plastic bottle with LHDPE twin bag port and cap x 100mL (net content). Box of 1’s. | Rx | Polifarma Ilac San. Ve Tic A.S.Turkey | Endure Medical, Inc. | DR-XY48034 | May 20, 2027 | |
Progyl DsMetronidazole | 500 mg Film-Coated TabletAlu/Deep Red PVC PVC Film Blister Pack of 10's (Box of 10's, 30's and 100's) | Rx | Phil. United Pharma CorporationPhilippines | ATC Healthcare International Corp. | DRP-14448 | Sep 6, 2028 | |
ProtozoleMetronidazole | 500 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Stallion Laboratories Pvt. LtdIndia | The Cathay Drug Co., IncImporter: Ambica International Corporation | DRP-4034 | Sep 24, 2028 | |
ProtozoleMetronidazole | 500 mg/100 mL (0.5% w/v) Solution for InjectionPlastic Bottle x 100 mL (Box of 1's) | Rx | Otsuka Pharmaceutical India Private LimitedIndia | The Cathay Drug Co., Inc.Importer: Otsuka (Philippines) Pharmaceutical, Inc. | DRP-1541-02 | Apr 25, 2028 | |
ProtozoleMetronidazole | 500 mg/100 mL Solution for Intravenous InfusionFFS LDPE Bottle x 100 mL Box of 1's | Rx | Ahlcon Parenterals (India) Ltd.India | The Cathay Drug Co., Inc.Importer: I.E. Medica, Inc. | DRP-5629-02 | Oct 17, 2029 | |
Q-ZolMetronidazole (as Benzoate) | 125 mg/5 mL Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Quad-Gen PharmaceuticalsTrader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-5591-03 | Feb 7, 2028 | |
QuinozoleMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for IV InfusionFFS LDPE Bottle x 100 mL (Box of 1's) | Rx | Ahlcon Parenterals (India) Ltd.India | MeedPharma Medical Supplies & Equipment DistributorImporter: I.E. Medica, Inc. | DRP-5629 | Oct 17, 2029 | |
RetazolMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1's) | Rx | Shijiazhuang No.4 Pharmaceutical Co., Ltd.China | Reta DrugImporter: Aglobal Care, Inc. | DRP-5460-05 | Jul 31, 2028 | |
RicozoleMetronidazole (as Benzoate) | 125 mg/5 mL Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Pharmahealth EnterprisesTrader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-5591-04 | Feb 7, 2028 | |
RicozoleMetronidazole | 500 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Pharmahealth EnterprisesTrader: Eadriex Pharmaceuticals Phils., Inc. | DRP-2420-03 | Feb 17, 2027 | |
RockzoleMetronidazole | 5 mg/ mL (500 mg/ 100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1’s) | Rx | Shijiazhuang No. 4 Pharmaceutical Co., LtdChina | Redrocks Pharma and Medical Supplies DistributionImporter: AGlobal Care, Inc. | DRP-5460-08 | Jul 31, 2028 | |
RodazidMetronidazole | 125 mg / 5 mL SuspensionAmber Glass Bottle x 60 mL and 120 mL Box of 1's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: PNSV ASIA CORPORATION | DR-XY22116 | Apr 30, 2031 | |
RodazidMetronidazole | 500 mg TabletAlu/PVC Blister Pack x 10’s Box of 100’s | Rx | Lloyd Laboratories, Inc.Philippines | Trader: PNSV ASIA CORPORATION | DR-XY18633 | Apr 13, 2029 | |
Siti-zoleMetronidazole | 5 mg/mL (500 mg/ 100 mL) Solution for I.V. Infusion.Polypropylene plastic infusion bottle x 100 (net content) Box of 's | Rx | Shijiazhuang No. 4 Pharmaceutical Co., LtdChina | Sahar International Trading Inc. | DR-XY47985 | Apr 28, 2027 | |
Siti-zoleMetronidazole | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene plastic infusion bottle x 100 (net content) (Box of 1's) | Rx | Shijiazhuang No.4 Co., Ltd.China | Sahar International Trading Inc. | DRP-16719 | Apr 28, 2027 | |
Strozole-500Metronidazole | 500 mg TabletAlu/PVC Blister Pack x 10's Box of 30's and 100's | Rx | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4034-01 | Sep 24, 2028 | |
SydenzoleMetronidazole | 500 mg TabletPaper Foil Strip x 10's (Box of 100's) | Rx | Sydenham Laboratories, Inc.Philippines | Sydenham Pharmaceuticals, Inc. | DRP-11633 | Jan 19, 2027 | |
TG-ZOLEMetronidazole | 500 mg TabletAlu-PVC Blister Pack x 10's (Box of 100's) | Rx | Scheele Laboratories Phils., Inc.Philippines | TGIF Pharmaceutical Trading Inc. | DRP-3941-02 | Jan 24, 2027 | |
Triconex ForteMetronidazole | 500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Multicare Pharmaceuticals Phils. Inc.Importer: Ambica International Corporation | DRP-4034-04 | Sep 24, 2028 | |
Trimetro IVMetronidazole | 5mg/mL Solution for Injection (IV Infusion)Transparent Colorless LDPE Bottle x 100 mL (Box of 1's) | Rx | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals & Pharmaceuticals Ltd.)India | S.M.H.P. Marketing & Consultancy | DRP-13543 | Mar 8, 2028 | |
TrinosaphMetronidazole (as benzoate) | 10 mg/g (1 % w/w) Topical GelLaminated Plastic Tube X 10g, 20g and (Box of 1's) | Rx | Azine Healthcare Pvt. Ltd.India | Ollen Pharma Trading, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13395 | Feb 10, 2028 | |
TrozodazMetronidazole | 500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL (Box of 1’s) | Rx | AXA Parenterals LimitedIndia | Central West Medicale Inc.Importer: Ambica International Corporation | DRP-6449-06 | Mar 5, 2030 | |
UnbrandedMetronidazole | 500 mg Film-Coated TabletAlu/Green PVC/PVDC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-11208 | Feb 15, 2032 | |
UnbrandedMetronidazole | 500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DRP-10685 | Nov 5, 2031 | |
UnbrandedMetronidazole | 500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Am-Europharma CorporationPhilippines | Ritemed Phils., Inc. | DRP-2377-01 | Apr 28, 2029 | |
VitazolMetronidazole | 5 mg/ mL (500 mg/ 100 mL) Solution for I.V. InfusionPolypropylene (PP) plastic bottle x 100 mL (net content) (Box of 1's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Vitalis Pharma Phil. Corp.Importer: AMB HK Enterprises Inc. | DRP-8458-01 | Oct 10, 2029 | |
XylomidMetronidazole | 500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-12008 | May 30, 2032 | |
ZolMetronidazole | 500 mg/100 mL Solution for Intravenous Infusion | Rx | Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China | Global Pharmatrade | DR-XY49641 | Feb 20, 2031 | |
ZolegylMetronidazole | 500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL (Box of 1’s) | Rx | AXA Parenterals LimitedIndia | D&G PharmaImporter: Ambica International Corporation | DRP-6449-03 | Mar 5, 2030 | |
ZolemetMetronidazole | 5 mg/mL Solution for IV InfusionType II Soda Lime Glass Bottle x 100 mL Not Applicable | Rx | Shandong Qidu Pharmaceutical Co., Ltd.China | Endure Medical, Inc.Trader: Xiamen Runcheng Group Co., Ltd. | DR-XY44760 | Sep 11, 2030 | |
ZolpasMetronidazole | 500 mg/100 mL Solution for I.V. InfusionLDPE Clear FFS Bottle x 100 mL (Box of 1’s) | Rx | Eurolife Healthcare Pvt. Ltd.India | Hexagon Pharmaceuticals | DR-XY47205 | Mar 19, 2031 | |
(no brand name)Metronidazole (As Benzoate) | 125 mg / 5 mL Oral SuspensionAmber boston round glass bottle with white aluminum screw cap x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DRP-11289 | Feb 23, 2027 | |
(no brand name)Metronidazole | 500 mg Film-Coated TabletAlu/Deep Red PVC PVC Film Blister Pack of 10's (Box of 10's, 30's and 100's) | Rx | Phil. United Pharma CorporationPhilippines | — | DRP-14447 | Sep 6, 2028 | |
(no brand name)Metronidazole | 500 mg Film-Coated TabletAlu/PVC Deep Red Film Blister Pack of 10’s (Box of 10's, 30's and 100's) | Rx | PHIL. UNITED PHARMA CORPORATIONPhilippines | Trader: Docteur's Choice Corporation | DRP-14449 | Sep 6, 2028 | |
(no brand name)Metronidazole | 500 mg Film-Coated TabletAlu/Deep Red PVC Film Blister Pack of 10's (Box of 10's, 30's and 100's) | Rx | PHIL. UNITED PHARMA CORPORATIONPhilippines | Trader: Golden Dale Pharma Corp. | DRP-14450 | Sep 6, 2028 | |
(no brand name)Metronidazole | 500 mg per 100 mL Solution For Iv InfusionPOLYPROPYLENE INFUSION BOTTLE | Rx | — | — | DRP-13486 | Feb 27, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
The boxed warning is shown at the top of this page.
Warnings and precautions (US label) US FDA label
WARNINGS Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions (SCARs) including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported with the use of metronidazole. Symptoms can be serious and potentially life threatening.
If symptoms or signs of SCARs develop, discontinue Metronidazole injection immediately and institute appropriate therapy. Central and Peripheral Nervous System Effects Severe neurological disturbances, including encephalopathy, cerebellar symptoms, convulsive seizures, peripheral neuropathy, optic neuropathy, and aseptic meningitis, have been reported in patients treated with metronidazole.
Encephalopathy associated with metronidazole may manifest as confusion or decreased level of consciousness, and is associated with widespread lesions on magnetic resonance imaging (MRI) of the brain. Cerebellar toxicity associated with metronidazole may manifest as ataxia, dizziness, dysarthria, nystagmus and saccadic pursuit and is accompanied by T2 flair lesions within the dentate nuclei seen on MRI.
Cerebellar toxicity may concurrently occur with encephalopathy, peripheral neuropathy or seizures. CNS symptoms and CNS lesions are generally reversible within days to weeks upon discontinuation of Metronidazole Injection. Peripheral neuropathy, usually symmetric and mainly of sensory type is characterized by numbness or paresthesia of an extremity.
Symptoms may be prolonged after drug discontinuation. Aseptic meningitis may occur within hours of dose administration and generally resolve after metronidazole therapy is discontinued (see ADVERSE REACTIONS). Advise patients to report neurologic symptoms that occur during metronidazole administration. Discontinue metronidazole treatment if any abnormal neurologic symptoms occur such as ataxia, dizziness, confusion or any other CNS adverse reaction (see ADVERSE REACTIONS).
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Disulfiram | Avoid | Psychotic reactions and confusion (label). | Contraindicated within 2 weeks of disulfiram. |
| Alcohol or propylene glycol products | Avoid | Disulfiram-like reaction (label). | Avoid during and for 3 days after therapy. |
| Warfarin | Adjust or monitor | Higher INR and bleeding risk (label). | Monitor INR; adjust warfarin. |
| Lithium | Adjust or monitor | Higher lithium levels and possible kidney damage (label). | Monitor lithium and creatinine. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedDrug interactions (US label) US FDA label
Drug Interactions
- Disulfiram Psychotic reactions and confusion have been reported in alcoholic patients who are using metronidazole and disulfiram concurrently. Do not administer Metronidazole Injection to patients who have taken disulfiram within the last two weeks (see CONTRAINDICATIONS).
- Alcoholic Beverages Abdominal cramps, nausea, vomiting, headaches, tachycardia and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following metronidazole therapy. Discontinue consumption of alcohol or products containing propylene glycol before, during and up to 72 hours after therapy with Metronidazole Injection (see CONTRAINDICATIONS).
- Warfarin and other Oral Anticoagulants Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time and increased risk of hemorrhages. When Metronidazole Injection is prescribed for patients on this type of anticoagulant therapy, prothrombin time and international normalized ratio (INR) should be carefully monitored and their anticoagulant dose adjusted accordingly. Monitor patients for signs and symptoms of bleeding.
- Lithium In patients stabilized on relatively high doses of lithium, short-term metronidazole therapy has been associated with elevation of serum lithium and, in a few cases, signs of lithium toxicity. Lithium toxicity may lead to renal damage. Frequent monitoring of serum lithium and serum creatinine levels is necessary.
- Busulfan Metronidazole has been reported to increase plasma concentrations of busulfan, which can result in an increased risk for serious busulfan toxicity such as sinusoidal obstruction syndrome, gastrointestinal mucositis, and hepatic veno-occlusive disease. Metronidazole Injection should not be administered concomitantly with busulfan unless the benefit outweighs the risk. If no therapeutic alternatives to metronidazole are available, and concomitant administration with busulfan is medically needed, frequent monitoring of busulfan plasma concentration should be performed and the busulfan dose should be adjusted accordingly.
- Drugs that Inhibit CYP450 Enzymes The simultaneous administration of drugs that decrease microsomal liver enzyme activity, such as cimetidine, may decrease metabolism and reduce plasma clearance of metronidazole which may result in metronidazole toxicity.
- Drugs that Induce CYP450 Enzymes The simultaneous administration of drugs that induce microsomal liver enzyme activity, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole and therefore decrease its efficacy.
- Cytochrome P450 3A4 (CYP3A4) substrates Concomitant use of Metronidazole Injection and CYP3A4 substrates (e.g., amiodarone, tacrolimus, cyclosporine, carbamazepine, phenytoin, and quinidine) may increase respective CYP3A4-substrate plasma levels. Monitoring of plasma concentrations of CYP3A4 substrates may be necessary.
- 5-Fluorouracil Metronidazole Injection decreases the clearance of 5-fluorouracil and may therefore cause 5-fluorouracil toxicity.
- Vecuronium Metronidazole Injection may potentiate the effects of vecuronium.
- Drugs that Prolong the QT interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval.
- Drug/Laboratory Test Interactions Metronidazole may interfere with certain types of determinations of serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides and glucose hexokinase. Metronidazole causes an increase in ultraviolet absorbance at 340 nm resulting in falsely decreased values.
Adverse reactions
Common
- Vaginal candidiasis
- Decreased appetite
- Confusion, insomnia (listed reactions; no rates given)
Serious
- Severe cutaneous adverse reactions (TEN, SJS, DRESS, AGEP)
- Encephalopathy, cerebellar toxicity, seizures, peripheral and optic neuropathy, aseptic meningitis
- Severe hepatotoxicity in Cockayne syndrome
- Leukopenia, neutropenia
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS The following reactions have been reported during treatment with metronidazole formulations: INFECTIONS AND INFESTATIONS: Vaginal candidiasis BLOOD AND LYMPHATIC SYSTEM DISORDERS: Agranulocytosis, Leukopenia, Neutropenia, Thrombocytopenia, Eosinophilia IMMUNE SYSTEM DISORDERS: Anaphylactic reaction, Hypersensitivity METABOLISM AND NUTRITION DISORDERS: Decreased appetite PSYCHIATRIC DISORDERS: Confusional state, Depression, Insomnia, Decreased libido NERVOUS SYSTEM DISORDERS: Encephalopathy, Seizure, Neuropathy peripheral, Ataxia, Dizziness, Hypoesthesia, Paresthesia, Dysgeusia, Headache, Nystagmus, Aseptic meningitis, Somnolence, Dysarthria, Numbness, Syncope EYE DISORDERS: Optic neuropathy, Saccadic eye movement EAR AND LABYRINTH DISORDERS: Vertigo, tinnitus, hearing impairment, hearing loss CARDIAC DISORDERS: QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. Flattening of the T-wave may be seen in electrocardiographic tracings, Tachycardia, Palpitation RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS: Dyspnea GASTROINTESTINAL DISORDERS: Pancreatitis, Abdominal pain, Diarrhea, Nausea, Vomiting, Asthenia, Proctitis HEPATOBILIARY DISORDERS: Hepatotoxicity/Liver Failure in patients with Cockayne syndrome (see CONTRAINDICATIONS), Jaundice SKIN AND SUBCUTANEOUS DISORDERS: Toxic epidermal necrolysis, Swelling face, Pruritus, Urticaria, Hyperhidrosis, Erythema, Rash; Stevens-Johnson syndrome, Fixed drug eruption, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP) (see WARNINGS) MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS: Muscle spasms, Arthralgia, Myalgia RENAL AND URINARY DISORDERS: Chromaturia, Dysuria Hepatic: Cases of severe irreversible hepatotoxicity/acute liver failure, including cases with fatal outcomes with very rapid onset after initiation of systemic use of metronidazole, have been reported in patients with Cockayne Syndrome (latency from drug start to signs of liver failure as short as 2 days) (see CONTRAINDICATIONS) REPRODUCTIVE: Dyspareunia GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: Injection site reaction, Malaise, Face edema, Edema peripheral, Chest pain, Chills INVESTIGATIONS: Hepatic enzyme increased.
Patients with Crohn's disease are known to have an increased incidence of gastrointestinal and certain extraintestinal cancers. There have been some reports in the medical literature of breast and colon cancer in Crohn's disease patients who have been treated with metronidazole at high doses for extended periods of time.
A cause and effect relationship has not been established. Crohn's disease is not an approved indication for Metronidazole Injection.
Monitoring parameters
- Neurologic symptoms (encephalopathy, cerebellar signs, seizures, peripheral or optic neuropathy, aseptic meningitis); liver function in hepatic impairment; INR with warfarin; lithium and creatinine with lithium (label). Kidney
- Neurologic symptoms
- Blood counts in long courses
- INR with warfarin
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Teratogenic Effects There are no adequate and well-controlled studies of Metronidazole Injection in pregnant women. There are published data from case-control studies, cohort studies, and 2 meta-analyses that include more than 5000 pregnant women who used metronidazole during pregnancy. Many studies included first trimester exposures.
One study showed an increased risk of cleft lip, with or without cleft palate, in infants exposed to metronidazole in utero; however, these findings were not confirmed. In addition, more than ten randomized, placebo-controlled clinical trials enrolled more than 5000 pregnant women to assess the use of antibiotic treatment (including metronidazole) for bacterial vaginosis on the incidence of preterm delivery.
Most studies did not show an increased risk for congenital anomalies or other adverse fetal outcomes following metronidazole exposure during pregnancy. Three studies conducted to assess the risk of infant cancer following metronidazole exposure during pregnancy did not show an increased risk; however, the ability of these studies to detect such a signal was limited.
Metronidazole crosses the placental barrier and its effects on the human fetal organogenesis are not known. Reproduction studies have been performed in rats, rabbits and mice at doses similar to the maximum recommended daily dose based on body surface area comparisons. There was no evidence of harm to the fetus due to metronidazole.
Healthcare provider should carefully consider the potential risks and benefits for each specific patient before prescribing Metronidazole Injection.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Metronidazole is present in human milk at concentrations similar to maternal serum levels, and infant serum levels can be close to or comparable to infant therapeutic levels. Because of the potential for tumorigenicity shown for metronidazole in mouse and rat studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Alternatively, a nursing mother may choose to pump and discard human milk for the duration of metronidazole therapy, and for 24 hours after therapy ends and feed her infant stored human milk or formula.
Mechanism of action
Mechanism of Action Metronidazole, a nitroimidazole, exerts antibacterial effects in an anaerobic environment against most obligate anaerobes. Once metronidazole enters the organism by passive diffusion and is activated in the cytoplasm of susceptible anaerobic bacteria, it is reduced; this process includes intra-cellular electron transport proteins such as ferredoxin, transfer of an electron to the nitro group of the metronidazole, and formation of a short-lived nitroso free radical.
Because of this alteration of the metronidazole molecule, a concentration gradient is created and maintained which promotes the drug’s intracellular transport. The reduced form of metronidazole and free radicals can interact with DNA leading to inhibition of DNA synthesis and DNA degradation leading to death of bacteria.
The precise mechanism of action of metronidazole is unclear.
US FDA labelPharmacokinetics
Key PK parameters
| Half-life | About 8 hours |
|---|---|
| Half-life in kidney failure (ESKD) kidney | Metronidazole unchanged; hydroxy and acetate metabolites accumulate (label) |
| Protein binding | Under 20% |
| Metabolism (CYP, transporters) | Side-chain oxidation and glucuronide conjugation |
| Active metabolites | Hydroxy metabolite (in vitro antimicrobial activity) |
| Renal excretion kidney | 60% to 80% of the dose in urine, about 20% of that as unchanged drug |
| Dialyzability kidney | Hemodialysis yes; peritoneal dialysis minimal (label) |
The average elimination half-life of metronidazole in healthy subjects is eight hours.
Excretion The major route of elimination of metronidazole and its metabolites is via the urine (60-80% of the dose), with approximately 20% of the amount excreted appearing as unchanged metronidazole.
Renal clearance of metronidazole is approximately 10 mL/min/1.73 m 2 .
Fecal excretion accounts for 6-15% of the dose.
The elimination half-life, measured during the first three days of life, was inversely related to gestational age.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY In patients treated with intravenous metronidazole, using a dosage regimen of 15 mg/kg loading dose followed 6 hours later by 7.5 mg/kg every 6 hours, the average peak steady-state plasma concentrations (C max) and trough concentrations (C min) were 25 mcg/mL and 18 mcg/mL, respectively. Plasma concentrations of metronidazole are proportional to the administered dose.
An eight-hour intravenous infusion of 100 mg to 4,000 mg of metronidazole in normal subjects showed a linear relationship between dose and peak plasma concentration. The average elimination half-life of metronidazole in healthy subjects is eight hours. Distribution Metronidazole is the major component appearing in the plasma, with lesser quantities of metabolites also being present.
Less than 20% of the circulating metronidazole is bound to plasma proteins. Metronidazole appears in cerebrospinal fluid, saliva and breast milk in concentrations similar to those found in plasma. Bactericidal concentrations of metronidazole have also been detected in pus from hepatic abscesses. Following a single intravenous dose of metronidazole 500 mg, 4 healthy subjects who underwent gastrointestinal endoscopy had peak gastric juice metronidazole concentrations of 5 to 6 mcg/mL at one hour post-dose.
In patients receiving intravenous metronidazole in whom gastric secretions are continuously removed by nasogastric aspiration, sufficient metronidazole may be removed in the aspirate to cause a reduction in serum levels. Metabolism The metabolites of metronidazole result primarily from side-chain oxidation [1-(ß-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-yl-acetic acid] and glucuronide conjugation.
Both the parent compound and the hydroxyl metabolite possess in vitro antimicrobial activity. Excretion The major route of elimination of metronidazole and its metabolites is via the urine (60-80% of the dose), with approximately 20% of the amount excreted appearing as unchanged metronidazole. Renal clearance of metronidazole is approximately 10 mL/min/1.73 m².
Fecal excretion accounts for 6-15% of the dose. Renal Impairment Decreased renal function does not alter the single-dose pharmacokinetics of metronidazole. Subjects with end-stage renal disease (ESRD; CL CR = 8.1±9.1 mL/min) and who received a single intravenous infusion of metronidazole 500 mg had no significant change in metronidazole pharmacokinetics but had 2-fold higher Cmax of hydroxy-metronidazole and 5-fold higher Cmax of metronidazole acetate, compared to healthy subjects with normal renal function (CL CR = 126 ± 16 mL/min).
Thus, on account of the potential accumulation of metronidazole metabolites in ESRD patients, monitoring for metronidazole associated adverse events is recommended (see PRECAUTIONS). Effect of Dialysis Following a single intravenous infusion or oral dose of metronidazole 500 mg, the clearance of metronidazole was investigated in ESRD subjects undergoing hemodialysis or continuous ambulatory peritoneal dialysis (CAPD).
A hemodialysis session lasting for 4 to 8 hours removed 40% to 65% of the administered metronidazole dose, depending on the type of the dialyzer membrane used and the duration of the dialysis session. If the administration of metronidazole cannot be separated from the dialysis session, supplementation of metronidazole dose following hemodialysis should be considered (see DOSAGE AND ADMINISTRATION).
A peritoneal dialysis session lasting for 7.5 hours removed approximately 10% of the administered metronidazole dose. No adjustment in metronidazole dose is needed in ESRD patients undergoing CAPD. Hepatic Impairment Following a single intravenous infusion of 500 mg metronidazole, the mean AUC 24 of metronidazole was higher by 114% in patients with severe (Child-Pugh C) hepatic impairment, and by 54% and 53% in patients with a mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment, respectively, compared to healthy control subjects.
There were no significant changes in the AUC 24 of hydroxy-metronidazole in these hepatically impaired patients. A reduction in metronidazole dosage by 50% is recommended in patients with severe (Child-Pugh C) hepatic impairment (see DOSAGE AND ADMINISTRATION). No dosage adjustment is needed for patients with mild to moderate hepatic impairment.
Patients with mild to moderate hepatic impairment should be monitored for metronidazole associated adverse events (see PRECAUTIONS and DOSAGE AND ADMINISTRATION). Geriatric Patients Following a single 500 mg oral or IV dose of metronidazole, subjects >70 years old with no apparent renal or hepatic dysfunction had a 40% to 80% higher mean AUC of hydroxy-metronidazole (active metabolite), with no apparent increase in the mean AUC of metronidazole (parent compound), compared to young healthy controls < 40 years old.
In geriatric patients, monitoring for metronidazole associated adverse events is recommended (see PRECAUTIONS). Pediatric Patients In one study newborn infants appeared to demonstrate diminished capacity to eliminate metronidazole. The elimination half-life, measured during the first three days of life, was inversely related to gestational age.
In infants whose gestational ages were between 28 and 40 weeks, the corresponding elimination half-lives ranged from 109 to 22.5 hours. Two other trials included infants 23-48 weeks post-menstrual age, (0-80 days postnatal age) with complicated intra-abdominal infections. Clearance increased with increasing post-menstrual age, while volume of distribution and half-life decreased (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION).
Microbiology Mechanism of Action Metronidazole, a nitroimidazole, exerts antibacterial effects in an anaerobic environment against most obligate anaerobes. Once metronidazole enters the organism by passive diffusion and is activated in the cytoplasm of susceptible anaerobic bacteria, it is reduced; this process includes intra-cellular electron transport proteins such as ferredoxin, transfer of an electron to the nitro group of the metronidazole, and formation of a short-lived nitroso free radical.
Because of this alteration of the metronidazole molecule, a concentration gradient is created and maintained which promotes the drug’s intracellular transport. The reduced form of metronidazole and free radicals can interact with DNA leading to inhibition of DNA synthesis and DNA degradation leading to death of bacteria.
The precise mechanism of action of metronidazole is unclear. Drug Resistance A potential for development of resistance exists against metronidazole. Resistance may be due to multiple mechanisms that include decreased uptake of the drug, altered reduction efficiency, overexpression of the efflux pumps, inactivation of the drug, and/or increased DNA damage repair.
Metronidazole does not possess any clinically relevant activity against facultative anaerobes or obligate aerobes. Activity In Vitro and in Clinical Infections Metronidazole has been shown to be active against most isolates of the following bacteria both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.
Gram-positive anaerobes Clostridium species Eubacterium species Peptococcus species Peptostreptococcus species Gram-negative anaerobes Bacteroides fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus) Fusobacterium species The following in vitro data are available, but their clinical significance is unknown. Metronidazole exhibits in vitro minimal inhibitory concentrations (MIC’s) of 8 mcg/mL or less against most (≥ 90%) isolates of the following bacteria; however, the safety and effectiveness of metronidazole in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.
Gram-negative anaerobes Bacteroides fragilis group (B. caccae, B. uniformis) Prevotella species (P. bivia, P. buccae, P. disiens) Susceptibility Tests For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: http://www.fda.gov/STIC.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Metronidazole 5 mg/mL, 100 mL Vial | ₱12.11–₱57.00Reference ₱14.17 | per vial | DPRI procurement range |
| Metronidazole 125 mg/5 mL, 60 mL Suspension | ₱15.00–₱69.00Reference ₱20.25 | per unit | DPRI procurement range |
| Metronidazole 500 mg Tablet | ₱0.85–₱3.85Reference ₱1.20 | per tablet | DPRI procurement range |
| 125 mg/5 mL (as base) or 200 mg/mL (as benzoate) suspension in 60 mL | ₱81.50 | per unit | PhilHealth GAMOT fixed fee |
| 250 mg tablet | ₱11.00 | per tablet | PhilHealth GAMOT fixed fee |
| 500 mg tablet | ₱13.25 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Metronidazole |
| PNF listing | Oral: 250 mg and 500 mg tablet |
| PNF listing | Oral: 125 mg base/5 mL (200 mg/5 mL (as benzoate)) suspension, 60 mL |
| PNF listing | Inj.: 5 mg/mL, 100 mL vial (IV infusion) |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Metronidazole · Civica, Inc. [US FDA-approved label, version 2, November 21, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=902ab25b-d493-495a-884e-96b080e9f72d
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Civica, Inc. (2025). Metronidazole injection USP [Prescribing information; US FDA-approved label, NDA018657, set ID 902ab25b-d493-495a-884e-96b080e9f72d, version effective November 21, 2025]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=902ab25b-d493-495a-884e-96b080e9f72d
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .